UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 夜間頻尿：臨床症状、診断、および治療治療 nocturia clinical presentation diagnosis and treatment
- 2. 女性における尿失禁の治療 treatment of urinary incontinence in women
- 3. 男性の尿失禁 urinary incontinence in men
- 4. 男性における下部尿路症状 lower urinary tract symptoms in men
- 5. 小児における膀胱機能障害のマネージメント management of bladder dysfunction in children
English Journal
- Antidiuretic effect of antimuscarinic agents in rat model depends on C-fibre afferent nerves in the bladder.
- Watanabe N, Akino H, Kurokawa T, Taga M, Yokokawa R, Tanase K, Nagase K, Yokoyama O.SourceDepartment of Urology, Faculty of Medical Science, University of Fukui, Fukui, Japan.
- BJU international.BJU Int.2013 Jul;112(1):131-6. doi: 10.1111/j.1464-410X.2012.11747.x. Epub 2013 Feb 22.
- WHAT'S KNOWN ON THE SUBJECT AND WHAT DOES THE STUDY ADD : Antichollnergic agents are anticipated to diminish storage symptoms, as well as nocturia. Nevertheless, the effect of this treatment on polyuria related to nocturia is not clear. By subgroup analysis of the data set from a phase III clinical
- PMID 23432937
- Imidafenacin for the treatment of overactive bladder.
- Maggiore UL, Scala C, Venturini PL, Ferrero S.SourceUniversity of Genoa, Institute for Cancer Research, San Martino Hospital and National, Department of Obstetrics and Gynecology , 16132 Genoa, Italy, Largo R. Benzi 1, 16132 Genoa , Italy +01139 010511525 ; +01139 010511525 ; simone.ferrero@unige.it.
- Expert opinion on pharmacotherapy.Expert Opin Pharmacother.2013 Jul;14(10):1383-97. doi: 10.1517/14656566.2013.796930. Epub 2013 May 6.
- Introduction: Imidafenacin (KRP-197/ONO-8025) is the latest antimuscarinic (AM) developed for the treatment of overactive bladder syndrome (OAB) and, at the moment, it is marketed only in Japan. This compound has been developed to improve the tolerability of AM therapy by binding specifically the M3
- PMID 23641864
- Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
- Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE.SourceDepartment of Urology, NYU Langone Medical Center, New York, NY, USA.
- International journal of clinical practice.Int J Clin Pract.2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21.
- INTRODUCTION: To examine pooled efficacy data from three, large phase III studies comparing mirabegron (50 and 100 mg) with placebo, and pooled safety data including additional mirabegron 25 mg and tolterodine extended release (ER) 4 mg results.METHODS: This prespecified pooled analysis of three
- PMID 23692526
Related Links
- The less you gotta go, the less you gotta worry Prescription DETROL ® LA (tolterodine tartrate extended release capsules) can help Just 1 DETROL LA capsule helps manage overactive bladder (OAB) symptoms like ...
- Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and incontinence. Learn about side effects, interactions and indications. ... Detrol side effects Get emergency medical help if you have any of these ...
Related Pictures
